Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis

被引：2

作者：

Mahmood, Aysal ^{[1
]}

Ali, Abraish ^{[1
]}

Haider, Hoorain ^{[1
]}

Zulfiqar, Beenish ^{[2
]}

机构：

[1] Dow Univ Hlth Sci DUHS, Karachi, Pakistan

[2] Univ Tennessee Hlth Sci Ctr, Memphis VA Med Ctr, Memphis, TN USA

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2023年 / 118卷

关键词：

D O I：

10.1016/j.ejim.2023.08.023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：152 / 154

页数：3

共 9 条

[1] Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Baraliakos, Xenofon
Gossec, Laure
Pournara, Effie
Jeka, Slawomir
Mera-Varela, Antonio
D'Angelo, Salvatore
Schulz, Barbara
Rissler, Michael
Nagar, Kriti
Perella, Chiara
Coates, Laura C.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) : 582 - 590
[2] Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Kavanaugh, Arthur
McInnes, Iain B.
Mease, Philip J.
Hall, Stephen
Chinoy, Hector
Kivitz, Alan J.
Wang, Zailong
Mpofu, Shephard
[J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1713 - 1717
[3] Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
McInnes, Iain B.
Mease, Philip J.
Ritchlin, Christopher T.
Rahman, Proton
Gottlieb, Alice B.
Kirkham, Bruce
Kajekar, Radhika
Delicha, Eumorphia-Maria
Pricop, Luminita
Mpofu, Shephard
[J]. RHEUMATOLOGY, 2017, 56 (11) : 1993 - 2003
[4] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
McInnes, Iain B.
Mease, Philip J.
Kirkham, Bruce
Kavanaugh, Arthur
Ritchlin, Christopher T.
Rahman, Proton
Van der Heijde, Desiree
Landewe, Robert
Conaghan, Philip G.
Gottlieb, Alice B.
Richards, Hanno
Pricop, Luminita
Ligozio, Gregory
Patekar, Manmath
Mpofu, Shephard
[J]. LANCET, 2015, 386 (9999) : 1137 - 1146
[5] Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Mease, Philip
van der Heijde, Desiree
Landewe, Robert
Mpofu, Shephard
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Boettcher, Elke
Navarra, Sandra
Meiser, Karin
Readie, Aimee
Pricop, Luminita
Abrams, Ken
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (06) : 890 - 897
[6] Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Nash, Peter
Mease, Philip J.
McInnes, Iain B.
Rahman, Proton
Ritchlin, Christopher T.
Blanco, Ricardo
Dokoupilova, Eva
Andersson, Mats
Kajekar, Radhika
Mpofu, Shephard
Pricop, Luminita
[J]. ARTHRITIS RESEARCH & THERAPY, 2018, 20
[7] Secukinumab in United States Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Nguyen, Tien
Churchill, Melvin
Levin, Robert
Valenzuela, Guillermo
Joseph, F. Merola .
Alexis, Ogdie .
Ana-Maria, Orbai .
Scher, Jose U.
Kavanaugh, Arthur
Kianifard, Farid
Rollins, Chauncy
Calheiros, Renato
Chambenoit, Olivier
[J]. JOURNAL OF RHEUMATOLOGY, 2022, 49 (08) : 894 - 902
[8] Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
van der Heijde, Desiree
Mease, Philip J.
Landewe, Robert B. M.
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Boettcher, Elke
Navarra, Sandra
Zhu, Xuan
Ligozio, Gregory
Readie, Aimee
Mpofu, Shephard
Pricop, Luminita
[J]. RHEUMATOLOGY, 2020, 59 (06) : 1325 - 1333
[9] Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dos-ing regimens
Zhang, Kai -Lin
Hou, Si-Yuan
Wu, Dan
[J]. CLINICS, 2021, 76

← 1 →